Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Farmacoterapia inmunosupresora para la prevención del rechazo posterior al trasplante pulmonar en la fibrosis quística

Información

DOI:
https://doi.org/10.1002/14651858.CD009421.pub4Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 19 junio 2018see what's new
Tipo:
  1. Intervention
Etapa:
  1. Review
Grupo Editorial Cochrane:

  1. Grupo Cochrane de Fibrosis quística y enfermedades genéticas

Copyright:
  1. Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • Ian J Saldanha

    Correspondencia a: Center for Evidence Synthesis in Health, Department of Health Services, Policy, and Practice, Brown University School of Public Health, Providence, USA

    [email protected]

    [email protected]

  • Oluwaseun Akinyede

    c/o Editorial Base, Cochrane Cystic Fibrosis and Genetic Disorders Review Group, Liverpool, UK

  • Karen A Robinson

    Department of Medicine, Johns Hopkins University, Baltimore, USA

Contributions of authors

TASK

WHO WILL UNDERTAKE THE TASK?

Protocol stage: draft the protocol

All authors

Review stage: select which studies to include (2 + 1 arbiter)

All authors

Review stage: extract data from studies (2 people)

Ian Saldanha and Oluwaseun Akinyede

Review stage: enter data into RevMan

Ian Saldanha

Review stage: carry out the analysis

Ian Saldanha

Review stage: interpret the analysis

All authors

Review stage: draft the final review

All authors

Update stage: update the review

All authors

Sources of support

Internal sources

  • No sources of support provided

External sources

  • National Institute for Health Research, UK

    This systematic review was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the Cochrane Cystic Fibrosis and Genetic Disorders Group.

Declarations of interest

The authors have no relevant conflicts of interest to declare.

Acknowledgements

We would like to acknowledge the previous work of Naomi McKoy who contributed greatly to previous versions of this review.

This project was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the Cochrane Cystic Fibrosis and Genetic Disorders Group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health.

Version history

Published

Title

Stage

Authors

Version

2018 Jun 19

Immunosuppressive drug therapy for preventing rejection following lung transplantation in cystic fibrosis

Review

Ian J Saldanha, Oluwaseun Akinyede, Karen A Robinson

https://doi.org/10.1002/14651858.CD009421.pub4

2015 Nov 10

Immunosuppressive drug therapy for preventing rejection following lung transplantation in cystic fibrosis

Review

Ian J Saldanha, Oluwaseun Akinyede, Karen A Robinson

https://doi.org/10.1002/14651858.CD009421.pub3

2013 Dec 09

Immunosuppressive drug therapy for preventing rejection following lung transplantation in cystic fibrosis

Review

Ian J Saldanha, Oluwaseun Akinyede, Karen A Robinson

https://doi.org/10.1002/14651858.CD009421.pub2

2011 Nov 09

Immunosuppressive drug therapy for preventing rejection following lung transplantation in cystic fibrosis

Protocol

Ian J Saldanha, Naomi A Mckoy, Karen A. Robinson

https://doi.org/10.1002/14651858.CD009421

Differences between protocol and review

Original review 2013

Following the peer review process:

  1. we added 'Hospitalisation' as a secondary outcome;

  2. we deleted the planned subgroup analysis "deceased versus living donor";

  3. added two new proposed subgroup analyses:

  • pre‐transplant LAS (higher versus lower)

  • pre‐transplant ventilator status (on versus off ventilation)

Update 2017

We will include a summary of findings table for each comparison presented in the review if further updates of this review include any studies.

Keywords

MeSH

Medical Subject Headings (MeSH) Keywords

Medical Subject Headings Check Words

Humans;

PICO

Population
Intervention
Comparison
Outcome

El uso y la enseñanza del modelo PICO están muy extendidos en el ámbito de la atención sanitaria basada en la evidencia para formular preguntas y estrategias de búsqueda y para caracterizar estudios o metanálisis clínicos. PICO son las siglas en inglés de cuatro posibles componentes de una pregunta de investigación: paciente, población o problema; intervención; comparación; desenlace (outcome).

Para saber más sobre el uso del modelo PICO, puede consultar el Manual Cochrane.

Study flow diagram.

Figuras y tablas -
Figure 1

Study flow diagram.

Ir a la figura de la revisiónAbrir en una pestaña nueva